Arbutus Biopharma Corporation (ABUS)
Company Info
| ISIN | CA03879J1003 |
|---|---|
| CUSIP | 03879J100 |
| Sector | Healthcare |
| Industry | Biotechnology |
Highlights
| Market Cap | $342.10M |
|---|---|
| EPS | -$0.46 |
| Revenue (TTM) | $22.24M |
| Gross Profit (TTM) | -$45.39M |
| EBITDA (TTM) | -$77.12M |
| Year Range | $1.69 - $3.15 |
| Target Price | $4.60 |
| Short % | 5.34% |
| Short Ratio | 11.95 |
Share Price Chart
Loading data...
Performance
The chart shows the growth of an initial investment of $10,000 in Arbutus Biopharma Corporation, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Compare to other instruments
Return
Arbutus Biopharma Corporation had a return of -12.88% year-to-date (YTD) and -12.88% in the last 12 months. Over the past 10 years, Arbutus Biopharma Corporation had an annualized return of -13.25%, while the S&P 500 had an annualized return of 9.87%, indicating that Arbutus Biopharma Corporation did not perform as well as the benchmark.
| Period | Return | Benchmark |
|---|---|---|
| Year-To-Date | -12.88% | 19.67% |
| 1 month | 10.33% | 8.42% |
| 6 months | -21.32% | 7.29% |
| 1 year | -12.88% | 12.71% |
| 5 years (annualized) | -14.20% | 10.75% |
| 10 years (annualized) | -13.25% | 9.87% |
Monthly Returns Heatmap
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | -0.80% | -7.63% | -5.65% | -6.45% | -0.00% | -9.85% | 12.02% |
Risk-Adjusted Performance
This table presents a comparison of risk-adjusted performance metrics for Arbutus Biopharma Corporation (ABUS) and S&P 500 (^GSPC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| Sharpe ratio | Sortino ratio | Omega ratio | Calmar ratio | Ulcer Index | |
|---|---|---|---|---|---|
ABUS Arbutus Biopharma Corporation | -0.32 | ||||
^GSPC S&P 500 | 0.91 |
Dividend History
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way.
Worst Drawdowns
The table below displays the maximum drawdowns of the Arbutus Biopharma Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Arbutus Biopharma Corporation was 97.19%, occurring on Oct 9, 2019. The portfolio has not yet recovered.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -97.19% | Mar 12, 2014 | 1406 | Oct 9, 2019 | — | — | — |
| -80.95% | Jan 20, 2011 | 213 | Nov 25, 2011 | 457 | Sep 26, 2013 | 670 |
| -36.08% | Nov 16, 2010 | 24 | Dec 20, 2010 | 20 | Jan 19, 2011 | 44 |
| -31.5% | Oct 8, 2013 | 46 | Dec 11, 2013 | 21 | Jan 13, 2014 | 67 |
| -18.01% | Feb 26, 2014 | 4 | Mar 3, 2014 | 2 | Mar 5, 2014 | 6 |
Volatility Chart
The current Arbutus Biopharma Corporation volatility is 13.19%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.